Clinical and biochemical study of D-serine metabolism among schizophrenia patients

El-Tallawy, Hamdy N; Saleem, Tahia H.; El-Ebidi, Abdallah Mahmoud; Hassan, Mohammed H.; Gabra, Romany H.; Farghaly, Wafaa Ma; El‐Maali, Nagwa Abo; Sherkawy, Hoda S

doi:10.2147/ndt.s126979

Cited by 22 publications

(18 citation statements)

References 43 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, it has been widely studied in schizophrenia patients. It was indicated that serum d-serine level was lower in patients with schizophrenia when compared to healthy control (Cho, Na, Cho, & Kang, 2016;El-Tallawy et al, 2017). d-amino acid oxidase (DAAO), the enzyme responsible for catabolism of the d-serine, was also found to be higher in schizophrenia patients when compared control group (El-Tallawy et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Alteration in NMDAR‐related amino acids in first episode psychosis

Garip

Kayır

2019

Synapse

View full text Add to dashboard Cite

The aim of the present study was to explore the role of N‐methyl‐D‐aspartate receptor (NMDAR) related amino acids in drug‐naive first episode psychosis (FEP) patients. The medication naïve patients with FEP (n = 40) and healthy volunteers with no family history of schizophrenia (n = 35) were recruited to the study and followed up for 10 weeks. Liquid chromatography–mass spectrometry method was used to measure plasma levels of the amino acids. The plasma glutamine, glutamic acid, proline, serine, asparagine, and hydroxyproline levels were significantly higher in the FEP patients compared to healthy controls (p values < .0001). The glutamine/glutamic acid ratio in FEP patients was not different from the healthy controls (p > .05). After the antipsychotic treatment, plasma glutamic acid, proline, and hydroxyproline levels were significantly increased (p values < .05) while the asparagine level and glutamine/glutamic acid ratio were decreased (p values < .05). The serine and glutamine levels did not show any differences with the treatment (p > .05). The initial plasma glutamine levels were negatively correlated with the initial Scale for the Assessment of Positive Symptoms (SAPS) score (r = −.45, p = .003). The initial plasma proline levels were negatively correlated with the initial and follow‐up SAPS scores (r = −.51 and −.39, p values < .05). The initial plasma proline and hydroxyproline levels were both negatively correlated with the initial Brief Psychiatric Rating Scale score (r = −.37, p = .017 and r = −.33, p = .033, respectively). Increase in NMDAR‐related amino acid levels during the FEP may be a compensatory response to glutamatergic hypofunction. Their plasma levels were significantly correlated with several psychotic symptoms before and after 10‐week treatment. Antipsychotic treatment has differential effects on the plasma levels of these amino acids.

show abstract

Section: Discussionmentioning

confidence: 99%

Alteration in NMDAR‐related amino acids in first episode psychosis

Garip

Kayır

2019

Synapse

View full text Add to dashboard Cite

show abstract

“…There is a growing body of evidence that D-serine protects against schizophrenia, and that its loss reduces activation of NMDA receptors, bringing about schizophrenic symptoms [ 45 , 46 , 113 , 114 , 115 , 116 ]. Indeed, a number of studies have found that giving schizophrenic patients high doses of D-serine mitigates negative symptoms of schizophrenia [ 45 , 117 , 118 , 119 ].…”

Section: Nmda Receptor Agonists or Co-agonistsmentioning

confidence: 99%

“…Indeed, a number of studies have found that giving schizophrenic patients high doses of D-serine mitigates negative symptoms of schizophrenia [ 45 , 117 , 118 , 119 ]. This is important because it has recently been shown that D-serine levels are significantly lower in humans suffering from Schizophrenia, probably caused by blunted expression of serine racemase and overexpression of DAAO [ 114 ]. D-Serine plays a role in the onset of Alzheimer’s Disease and dementias [ 33 , 43 , 47 , 120 ].…”

Section: Nmda Receptor Agonists or Co-agonistsmentioning

confidence: 99%

Advances in D-Amino Acids in Neurological Research

Seckler

Lewis

2020

IJMS

View full text Add to dashboard Cite

D-amino acids have been known to exist in the human brain for nearly 40 years, and they continue to be a field of active study to today. This review article aims to give a concise overview of the recent advances in D-amino acid research as they relate to the brain and neurological disorders. This work has largely been focused on modulation of the N-methyl-D-aspartate (NMDA) receptor and its relationship to Alzheimer’s disease and Schizophrenia, but there has been a wealth of novel research which has elucidated a novel role for several D-amino acids in altering brain chemistry in a neuroprotective manner. D-amino acids which have no currently known activity in the brain but which have active derivatives will also be reviewed.

show abstract

“…Ïîìèìî ýòîãî, îáíàðóaeèâàþòñÿ çíà÷èòåëüíî áîëåå âûñîêèå óðîâíè àëàíèíà, ãëèöèíà, ëåéöèíà è ôåíèëàëàíèíà â ñïèííîìîçãîâîé aeèäêîñòè ïàöèåíòîâ ñ øèçîôðåíèåé ïî ñðàâíåíèþ ñ çäîðîâûìè ëþäüìè [31]. Ïîëîaeåíèå, ÷òî íàðóøåííûé ìåòàáîëèçì D-ñåðèíà ìîaeåò ÿâëÿòüñÿ ïðåäèêòîðîì øèçîôðåíèè, íàøëî ïîäòâåðaeäåíèå è â ïîñëåäíèõ ñòàòüÿõ [32,33]. S. Saleem ñ ñîàâò.…”

Section: изучение роли аминокислот и ацилкарнитинов в патогенезе шизоunclassified

Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy

et al. 2020

View full text Add to dashboard Cite

Background. Schizophrenia is a socially significant mental illness with insufficiently studied etiology and pathogenesis. A number of hypotheses of schizophrenia pathogenesis (dopamine, glutamate, kinurenin and serotonin hypotheses) bring together the fact that amino acids are precursors or intermediate metabolic products of these metabolites. Amino acids and their metabolites play an important role as significant substrates and regulators in many metabolic pathways.The aim of this review is to analyze the literature data on the studies of amino acids and acylcarnitines in patients with schizophrenia.Methods. A literature search was conducted using PubMed databases for articles published in English and covering the period from the first articles on this topic, dated 1977 to April 2019. Combinations of the following keywords were used to search for “schizophrenia”, “antipsychotics” and “amino acids”, “acylcarnitines”, “metabolomics”.Results. The review summarizes the data on the content of amino acids and acylcarnitines in the peripheral blood of schizophrenia patients and their dynamics in the course of pharmacotherapy with antipsychotic drugs. The potential of determining amino acids as biomarkers of therapeutic response and side effects, as well as their use in the treatment of patients with schizophrenia, are considered.Conclusion. Further investigation of the spectrum of amino acids and their metabolites with the using of mass spectrometric methods of metabolic analysis can lead to the discovery of new therapeutic targets and strategies, assess their role in the pathophysiology of schizophrenia, identify mechanisms that ensure the development of antipsychotic antipsychotics, and drug-induced side effects antipsychotics, in particular, metabolic syndrome.

show abstract

Clinical and biochemical study of D-serine metabolism among schizophrenia patients

Cited by 22 publications

References 43 publications

Alteration in NMDAR‐related amino acids in first episode psychosis

Alteration in NMDAR‐related amino acids in first episode psychosis

Advances in D-Amino Acids in Neurological Research

Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy

Contact Info

Product

Resources

About